Trend Revising? Biotech IPOs Slow Sharply In HK While Shanghai's STAR Shines

Just one year ago, biotechs were queuing up to list in Hong Kong following a relaxation of rules, but now many are postponing plans or simply shifting away, impacted by the market's low valuations, fast-changing environment and surprisingly strong competition from a new Shanghai trading section.